Focused On-demand Library for Complement factor B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P00751

UPID:

CFAB_HUMAN

Alternative names:

C3/C5 convertase; Glycine-rich beta glycoprotein; PBF2; Properdin factor B

Alternative UPACC:

P00751; B0QZQ6; O15006; Q29944; Q53F89; Q5JP67; Q5ST50; Q96HX6; Q9BTF5; Q9BX92

Background:

Complement factor B, also known as C3/C5 convertase, plays a crucial role in the alternative pathway of the complement system. It is cleaved into two fragments, Ba and Bb, with Bb acting as a serine protease that combines with complement factor 3b to generate the C3 or C5 convertase. This protein is also involved in the proliferation and differentiation of preactivated B-lymphocytes, among other immune responses.

Therapeutic significance:

Complement factor B is implicated in several diseases, including age-related macular degeneration, atypical hemolytic uremic syndrome, and complement factor B deficiency. These associations highlight its potential as a target for therapeutic intervention in conditions related to the immune system and beyond.